Cigna Corporation

(New York Stock Exchange)

Cigna (CI) stock at a glance

Full Cigna report
Ticker
CI
Exchange
New York Stock Exchange
News sentiment · last 30 days
+35 Somewhat Bullish ▼ -7 vs. previous 30 days
30-day average of 13 articles · scale −100 to +100

Across 13 scored articles from Oct 16 to Nov 14, 2026 (UTC), the average sentiment of Cigna news is Somewhat Bullish (+35) on a scale from −100 to +100. That is down 7 points from the previous 30 days (+42).

+45 Somewhat Bullish 1 article

Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.

Articles

67
Show Summary
Show Bulletpoints
Detailed View
Bullish +75

Cigna (CI) Gets a Buy from Bernstein

AI-generated analysis

Bernstein analyst Lance Wilkes has maintained a Buy rating on Cigna (CI) and set a price target of $358.00. Wilkes covers the Healthcare sector, with his recent recommendations including stocks such as Cigna, Centene, and CVS Health. According to TipRanks data, Wilkes has an average return of -8.7% and a 32.67% success rate on recommended stocks. The broader analyst consensus for Cigna suggests a Strong Buy rating, with an average price target of $342.62. Additionally, Bernstein had previously upgraded Cigna to Outperform from Market Perform. Cigna's most recent financial results show the company reported a quarterly revenue of $72.47 billion and a net profit of $1.23 billion for the quarter ending December 31. In comparison to the same period last year, the company earned a revenue of $65.65 billion but had a net profit of $1.42 billion. The news follows broader market updates, including midday reports that Dick's Sporting Goods and Dollar General reported quarterly beats. The article also references other market movements, noting that CVS was upgraded while General Mills was downgraded by Wall Street analysts. Additional headlines mentioned include a lawsuit where a Department sues New York-Presbyterian over allegedly anticompetitive contracts, and various calendar items regarding oil prices and Canadian oil stocks. The content includes standard disclaimers indicating that the Globe and Mail has not reviewed this third-party content and may receive compensation for its placement on the site.

📈 Bernstein analyst sets Cigna price target at $358 with Buy rating.

💰 Quarterly revenue reached $72.47 billion, up from prior year's $65.65B.

⚠️ Net profit decreased to $1.23 billion compared to $1.42 billion last year.

📈 Bernstein analyst Lance Wilkes maintains a Buy rating on Cigna (CI) and sets a new price target of $358.00.

💰 The company reported quarterly revenue of $72.47 billion for the quarter ending December 31, up from $65.65 billion the prior year.

⚖️ Net profit decreased to $1.23 billion compared to $1.42 billion in the same period last year.

🤝 The wider street consensus rates Cigna as a Strong Buy with an average analyst price target of $342.62.

🩺 Analyst Lance Wilkes covers the Healthcare sector, including stocks such as Centene and CVS Health.

📊 TipRanks data indicates Wilkes has an average return of -8.7% with a 32.67% success rate on recommended stocks.

⚠️ Content is syndicated from third-party sources, including paid content and unreviewed press releases.

Bullish Signals
  • Analyst maintained Buy rating on Cigna with price target of $358.
  • Street consensus shows Strong Buy rating with average price target of $342.62.
  • Cigna reported quarterly revenue of $72.47B and net profit of $1.23B.
Bullish Signals
  • Bernstein analyst Lance Wilkes maintained a Buy rating on Cigna (CI) with a price target of $358.00, indicating strong investor confidence.
  • The Street suggests a Strong Buy analyst consensus rating for Cigna with an average price target of $342.62 across Wall Street analysts.
  • Cigna reported quarterly revenue of $72.47 billion and a net profit of $1.23 billion for the quarter ending December 31, demonstrating solid financial performance.
Risk Factors
  • Analyst Lance Wilkes at Bernstein has an average return of -8.7% on recommended stocks, suggesting the quality of his past calls may be subpar.
Bullish +75

Cigna: Flashing A Buy For Dividend Growth And Deep Value

AI-generated analysis

The Cigna Group (CI) is evaluated as a Buy, primarily based on anticipated double-digit adjusted income per share growth expected to resume in 2027 and beyond. Key drivers for this top-line and margin expansion include growth in the pharmacy segment, adoption of biosimilars, behavioral health expansion, and aggressive share buybacks. The stock currently trades at an 8.5x forward P/E ratio, which represents a 29% discount to its estimated fair value, supporting a projected annual total return of 17% through 2031. Dividend safety is considered robust for Cigna, characterized by a low-20% payout ratio and an A+ Quant grade, positioning the company for continued and accelerating dividend growth. The analysis emphasizes the importance of specific financial anatomy when evaluating newcomers to the dividend growth sector, highlighting factors such as a dominant market position, a payout ratio that provides room for error, and a management team capable of driving value creation. Scott Kaufman serves as the lead analyst for Dividend Kings and brings over a decade of experience in the financial sector to his analysis. He aims to provide actionable insights into high-quality dividend growth and undervalued opportunities to secure robust total returns through cash dividends and strong capital gains. The team behind this analysis includes Kody's Dividends, Justin Law, and Rachel Kaufman. The author holds a beneficial long position in Cigna shares either through stock ownership or derivatives but states he is not receiving compensation for the article other than from Seeking Alpha. Seeking Alpha discloses that analysts are third-party authors who may not be licensed or certified by regulatory bodies and notes that past performance does not guarantee future results.

📈 Cigna Group maintains 'Buy' rating with double-digit EPS growth expected from 2027.

💊 Growth drivers include pharmacy expansion and aggressive share buybacks.

📊 Stock trades at 8.5x forward P/E, a 29% discount to fair value.

🤲 Low-20% payout ratio supports dividend safety with robust growth capacity.

📈 Cigna Group (CI) maintains a 'Buy' rating with catalysts for double-digit adjusted income per share growth expected to resume in 2027 and beyond.

💊 Growth drivers include expansion in the pharmacy segment, biosimilar adoption, behavioral health services, and aggressive share buybacks.

📊 The stock trades at an 8.5x forward P/E, representing a 29% discount to fair value.

🏦 Investors project a potential 17% annual total return for Cigna through the year 2031 based on current valuation metrics.

🤲 Dividend safety is highlighted by a low-20% payout ratio and an A+ Quant grade, indicating robust capacity for dividend growth.

👨‍💼 Scott Kaufman of Dividend Kings describes the company as having the financial anatomy typical of high-quality dividend growers with dominant market position.

⚠️ The author discloses a beneficial long position in Cigna shares but notes they did not receive compensation specifically for this article.

⚖️ Seeking Alpha and its third-party analysts disclaim that past performance is no guarantee of future results.

📉 No formal investment recommendation or suitability advice is given regarding whether the stock fits an individual investor's specific portfolio needs.

🔒 Seeking Alpha clarifies it is not a licensed securities dealer, broker, or US investment adviser.

Bullish Signals
  • Cigna Group remains a Buy rating with double-digit income growth expected from 2027.
  • Pharmacy segment and share buybacks drive topline and margin growth.
  • Shares trade at 8.5x forward P/E, a 29% discount supporting 17% annual returns through 2031.
  • Low-20% payout ratio supports continued, accelerating dividend growth.
Risk Factors
  • No negative points or risks were identified.
  • Analyst holds beneficial long position in Cigna shares.
Bullish Signals
  • Cigna Group remains a Buy rating with catalysts for double-digit adjusted income per share growth expected to resume in 2027 and beyond.
  • Pharmacy segment, biosimilar adoption, behavioral health expansion, and aggressive share buybacks are driving both topline and margin growth.
  • Shares trade at an 8.5x forward P/E, representing a 29% discount to fair value, which supports a projected 17% annual total return through 2031.
  • Dividend safety is robust with a low-20% payout ratio and A+ Quant grade, positioning CI for continued, accelerating dividend growth.
Risk Factors
  • No negative points or risks were identified in this article; the entire text is positive, focusing on buy recommendations, growth catalysts, undervaluation, dividend safety, and analyst credentials.
  • The article contains an analyst disclosure stating they have a beneficial long position in Cigna shares, which creates a potential conflict of interest that could bias the bullish recommendation.
Somewhat Bullish +50

2026 Just Capital rankings: See the companies on the annual list of corporate leaders

AI-generated analysis

The 2026 Just Capital rankings were released to identify America's "most just" companies within the Russell 1000 universe. Developed by Just Capital, the annual list utilizes a methodology grounded in public polling that has surveyed approximately 200,000 Americans since 2015 to gauge issues central to just business behavior. The evaluation process for this year's rankings analyzed 17 core issues across 85 overall data points and 36 sector-specific data points. These assessments covered five stakeholder groups: workers, communities, shareholders and governance, customers, and the environment. This comprehensive framework aims to highlight corporate leaders even as boardrooms navigate heightened uncertainty from geopolitical instability, inflation, and artificial intelligence developments. The full list of top-ranked corporations includes HP Inc at number one, followed by Union Pacific Corp, Hewlett Packard Enterprise Company, Dow Inc, and S&P Global Inc in the top five positions. Notable technology and healthcare firms such as NVIDIA Corp, Salesforce.com Inc, and Abbott Laboratories also secured placements on the list. Among financial services, The Hartford Insurance Group ranked eighth, while M&T Bank Corp placed ninth. The rankings extend down to position 105 with Edison International holding that spot in this year's compilation of corporate leaders who have prioritized stakeholder value. The third-ranked company, Hewlett Packard Enterprise Company, sits alongside other major players like Micron Technology Inc at number six and Accenture plc at number nine. Financial institutions remain prominent throughout the top 100, with Visa Inc ranking 34th, American Express Company at 87th, and Citigroup not appearing in the top 105 but The Cigna Group holding position 13 as a major healthcare leader. The release emphasizes that despite pressure to maximize bottom-line results and navigate potential ESG and DEI shifts during the second Trump administration, "just" investments remain a focus for stakeholders including investors, workers, and communities seeking future returns. The article highlights that while companies face increased pressure to deliver financial performance and steer clear of political entanglements, there is a strategic shift in where these sustainable investments are being directed. This approach seeks to maximize future returns across all stakeholder groups without retreating from core social and environmental responsibilities. The Just Capital rankings thus serve as a tool for identifying corporations that maintain their commitment to ethical practices even amidst significant market volatility and changing regulatory landscapes under current government administrations.

🏆 Just Capital released 2026 rankings of America's most ethical companies.

💼 HP Inc., Union Pacific, and Hewlett Packard Enterprise led the Russell 1000.

📊 Analysis covered 17 issues across five stakeholder groups using 85+ data points.

🌍 Investors now seek ethical performance that balances people and profits.

🏆 Just Capital released its 2026 annual rankings identifying the "most just" companies in America using public polling data.

🔍 The methodology analyzes 17 core issues across five stakeholder groups: workers, communities, shareholders, customers, and the environment.

⚠️ Corporate leaders are facing unprecedented uncertainty regarding geopolitics, inflation, and AI while shifting away from traditional ESG commitments.

💼 The Russell 1000 universe was ranked, with HP Inc., Union Pacific, and Hewlett Packard Enterprise securing the top three spots.

🩺 Cigna Group (CI) ranked 13th on the list in this year's edition of Just Capital corporate leaders.

📉 Investors are adapting by moving capital into sectors that balance ethical considerations with strong bottom-line performance for workers and communities.

🧮 The annual research process evaluated over 85 overall data points and 36 sector-specific data points to determine final standings.

💡 Companies are pivoting investments to maximize future returns while avoiding political controversy in their sustainability strategies.

Bullish Signals
  • Cigna Group (CI) ranked #13 most just by Just Capital.
  • Analysis covered over 85 data points across five stakeholder groups.
  • CI joins top leaders like HP Inc and Accenture on the list.
  • Top rankings achieved despite challenging economic landscape and inflation.
  • Shift toward 'just' investments maximizes future returns for all stakeholders.
Risk Factors
  • Trump era retreat from ESG/DEI creates compliance risks for firms like Cigna.
  • Geopolitics and AI adoption pressure bottom lines despite investment commitments.
  • 2026 rankings use subjective polling potentially misaligned with financial performance.
  • Stakeholder priority shifts may dilute shareholder value and increase costs.
Bullish Signals
  • The Cigna Group (CI) has been recognized as the #13 most just company on the 2026 Just Capital rankings, highlighting its strong standing in ESG and DEI despite recent industry shifts.
  • Just Capital's rigorous methodology evaluated over 85 data points across five stakeholder groups, including workers, communities, shareholders, customers, and the environment to determine the list.
  • The ranking identifies top-tier corporate leaders like HP Inc (Rank 1), Union Pacific (Rank 2), and Accenture (Rank 9) alongside CI, validating CI's position among America's best performers.
  • The recognition comes amidst a challenging economic landscape with geopolitical uncertainty and inflation, suggesting these companies are successfully navigating complex challenges while maintaining high standards.
  • There is an emerging shift where 'just' investments are being made to maximize future returns for all stakeholders, from investors to workers and communities, positioning CI as a leader in this strategic evolution.
Risk Factors
  • Companies are retreating from ESG and DEI initiatives during the second Trump administration, potentially creating reputational and compliance risks for ranked firms like Cigna.
  • Corporate boardrooms face heightened uncertainty from geopolitics, inflation, and AI adoption, which could pressure bottom-line delivery despite 'just' investment commitments.
  • The 2026 rankings are based on public polling that prioritizes issues contributing to 'just business behavior,' a subjective metric that may not align with traditional financial performance standards.
  • Investors face shifting priorities toward maximizing returns for stakeholders from workers to communities, which could dilute shareholder value and increase cost structures.
  • The article notes pressure mounts to deliver on the bottom line while steering clear of politics, suggesting companies must navigate conflicting demands that could impact strategic focus.
Bullish +65

Bernstein Upgrades The Cigna Group (CI) From “Market Perform” to “Outperform”

AI-generated analysis

Bernstein has upgraded The Cigna Group (NYSE:CI) from "Market Perform" to "Outperform," citing several positive catalysts that could drive investor confidence. The upgrade comes alongside slightly raised earnings-per-share (EPS) estimates for the 2027-2030 period, while maintaining the 2026 estimate. Analysts expect the company's stock multiple to increase over time due to key drivers including the Pharmacy Benefit Manager reform bill, the FTC settlement, already announced PBM model changes, and the economic impacts Cigna has guided. The firm set a price target of $358 for the stock. In conjunction with the upgrade, The Cigna Group reiterated its 2026 financial projections on March 3, 2026. Management estimates consolidated adjusted income from operations of at least $30.25 per share. The company also emphasized stability across its major sectors by restating projections for Evernorth's pre-tax adjusted income from operations of at least $6.9 billion and Cigna Healthcare's pre-tax adjusted income from operations of at least $4.5 billion. As a global provider of health services, Cigna offers pharmacy benefit management, specialty pharmacy, care delivery, and medical insurance solutions through its Evernorth Health Services and Cigna Healthcare segments worldwide. Separately, analysts at JPMorgan Chase & Co. commented on the company's recent leadership changes, noting that CEO Cordani's retirement came as a surprise to them. However, they expressed confidence in new leadership under the appointment of CEO Brian Evanko. Earlier reports also noted that The Cigna Group is among the 11 best very cheap stocks to buy according to billionaires. While acknowledging CI's investment potential, the article includes commentary suggesting that certain AI stocks may offer greater upside potential and carry less downside risk. This perspective mentions looking for an extremely undervalued AI stock benefiting from Trump-era tariffs and onshoring trends, directing readers to a free report. The text concludes with a disclosure stating there is none and follows up with links to related articles about stocks that could double in 3 years or make one rich in 10 years.

📈 Bernstein upgrades Cigna to Outperform with a $358 price target.

💰 Management projects 2026 income of $30.25 per share.

👋 Investors remain confident in new CEO Brian Evanko despite transition.

⚖ Confidence driven by PBM reform, settlements, and model changes.

📈 Bernstein upgraded The Cigna Group (CI) from "Market Perform" to "Outperform."

💵 Analysts set a $358 price target for the stock following the upgrade.

🏥 Management reiterated its 2026 projection of at least $30.25 per share in consolidated adjusted income from operations.

💊 The company expects Evernorth's pre-tax adjusted income to be at least $6.9 billion.

🦠 Cigna Healthcare is projected to generate at least $4.5 billion in pre-tax adjusted income from operations.

📉 Analysts slightly raised EPS estimates for the years 2027 through 2030 while keeping the 2026 estimate unchanged.

⚖️ Investor confidence is driven by PBM reform, FTC settlements, announced model changes, and guided economic impacts.

👋 CEO Cordani's retirement was seen as a surprise, but analysts remain confident in new CEO Brian Evanko.

🌐 Cigna operates globally offering pharmacy benefit management, specialty pharmacy, care delivery, and medical insurance solutions.

📉 The article notes that while CI is an investment, AI stocks may offer greater upside potential with less risk.

📄 Disclosure indicates none and encourages readers to follow Insider Monkey on Google News.

Bullish Signals
  • Bernstein upgraded The Cigna Group (CI) from 'Market Perform' to 'Outperform', reflecting strong analyst confidence in the stock's prospects.
  • The firm established a $358 price target, indicating significant upside potential relative to current market prices.
  • Analysts expect the company's stock multiple to increase over time due to positive drivers such as PBM reform bill impacts and favorable economic conditions.
  • Management slightly raised EPS estimates for 2027-2030, signaling long-term growth visibility and operational stability.
  • The company reiterated its 2026 projection with an estimated consolidated adjusted income from operations of at least $30.25 per share.
  • Cigna Healthcare is projected to generate at least $4.5 billion in pre-tax adjusted income from operations for 2026, reinforcing core business strength.
  • Management maintained stability across major sectors by restating Evernorth's projection for at least $6.9 billion in pre-tax adjusted income from operations.
  • Analysts at JPMorgan Chase & Co. expressed confidence in the company's new leadership transition under CEO Brian Evanko following the departure of Cordani.
Risk Factors
  • Analysts at JPMorgan Chase & Co. noted that the retirement of CEO Cordani came as a surprise, raising questions about leadership continuity despite their expressed confidence in new CEO Brian Evanko.
  • While Bernstein upgraded the stock, analysts from other firms argue that AI stocks currently offer greater upside potential and carry less downside risk than Cigna (CI).
  • The article suggests that investors looking for short-term gains driven by Trump-era tariffs or onshoring trends should consider AI stocks instead of CI.
  • Despite the 'Outperform' rating and price target increase, the stock is presented as a secondary option compared to emerging AI equities in the current market landscape.
Somewhat Bullish +45

Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?

AI-generated analysis

Cigna Group Inc. trades at a forward price-to-earnings ratio of 8.61x, which is notably lower than the industry average of 13.45x, suggesting a potentially undervalued position despite its shares declining 3.4% year to date against an industry decline of 13.5%. The company operates through two primary segments, Cigna Healthcare and Evernorth Health Services, with a market capitalization of $68.8 billion. Analysts maintain a Zacks Rank #3 (Hold) for the stock, supported by a strong A Value Score and a consensus estimate projecting 2026 earnings at $30.29 per share, representing a 1.5% year-over-year increase, while revenues are expected to grow 3.5% to $284.4 billion. Cigna has demonstrated consistent performance by beating earnings estimates in each of the last four quarters with an average surprise of 2.7%, and its adjusted income from operations rose 4% in 2025 driven primarily by growth in the Evernorth Health Services segment, which reported $235 billion in revenue for the year. Strategic initiatives are aimed at enhancing shareholder value and operational efficiency, including a share repurchase program where the company bought back 11.9 million shares for approximately $3.6 billion in 2025, and an increase in the quarterly dividend to $1.56 per share in early 2026. The Evernorth Health Services division introduced a transformative pharmacy benefits model that passes manufacturer discounts directly to customers at the point of sale, with Cigna Healthcare planning to adopt this for fully insured customers starting in 2027. These business mix shifts and digital transformation efforts reduced the adjusted selling, general, and administrative expense ratio to 5.0% in 2025, although the company expects adjusted operating income to reach at least $7.95 billion by 2026. However, investors should monitor several headwinds that could impact margin growth. Total benefits and expenses escalated significantly, increasing by 27% in 2024 and 12% in 2025 due to higher pharmacy and service costs, with the medical cost ratio deteriorating 120 basis points year over year to 84.4% in 2025. Additionally, Cigna faces elevated leverage levels, holding long-term debt of $30.9 billion at the end of 2025 compared to a cash balance of $7.7 billion, which may sustain pressure on interest expenses going forward. The article concludes by noting other better-ranked stocks in the broader medical space, such as Catalyst Pharmaceuticals and Enovis Corporation, which hold a Zacks Rank #1 (Strong Buy) with more robust recent earnings beats compared to Cigna's current Hold status.

🏢 Cigna operates via Healthcare and Evernorth segments with a $68.8B market cap and forward P/E of 8.61x.

📉 Shares dropped 3.4% YTD while beating earnings estimates for four consecutive quarters.

⚡ Adjusted income rose 4% in 2025 as revenue grew 3.5% to $284.4 billion by 2026.

💸 Expenses escalated significantly, with total benefits rising 12% despite improved SG&A ratios.

🩺 Investors face margin pressure from escalating costs while the dividend yield remains robust.

🏢 Cigna operates through two main segments: Cigna Healthcare and Evernorth Health Services, offering medical plans and pharmacy solutions.

💰 The company has a market capitalization of $68.8 billion and trades with a forward P/E ratio of 8.61x, which is lower than the industry average of 13.45x.

📉 Shares have lost 3.4% year-to-date, yet this loss is less severe than the industry’s 13.5% decline over the same period.

🔒 Cigna holds a Zacks Rank #3 (Hold) and carries a Value Score of A based on current market analysis.

📈 The consensus estimate for 2026 earnings is pegged at $30.29 per share, suggesting a 1.5% year-over-year increase.

💵 Estimated revenue for 2026 is pinned at $284.4 billion, indicating 3.5% year-over-year growth.

📊 The company beat earnings estimates in each of the trailing four quarters, with an average surprise of 2.7%.

⚡ Adjusted income from operations rose 4% in 2025, driven by strong growth in the Evernorth Health Services segment.

🏥 Evernorth Health Services’ adjusted revenues increased 16% in 2025 to $235 billion as the company adopted a new pharmacy benefits model.

💸 Adjusted SG&A expense ratio dropped to 5.0% in 2025 due to business mix shifts and digital transformation efforts.

🤝 The quarterly dividend was increased to $1.56 per share in early 2026 from $1.51 in 2025, signaling confidence in long-term cash flow.

📉 Total benefits and expenses escalated 27% in 2024 and 12% in 2025, with the medical cost ratio deteriorating to 84.4%.

💳 The company reported a significant debt level with $30.9 billion in long-term debt at the end of 2025 compared to $7.7 billion in cash.

🩺 Investors should monitor persistent expense escalation which might weigh on margin growth despite strong operational performance.

🔍 Other medical space stocks like Catalyst Pharmaceuticals, Enovis, and USANA currently hold higher Zacks Ranks #1 (Strong Buy).

🚀 The Zacks Top 10 Stocks portfolio has gained +2,530.8% since inception in 2012, significantly outperforming the S&P 500.

Bullish Signals
  • CI shares lost only 3.4% YTD vs industry decline.
  • Trades at forward P/E of 8.61x, below industry average.
  • Beat earnings estimates for four trailing quarters.
  • Adjusted income from operations rose 4% year-over-year.
  • Evernorth Health Services revenues increased 16% to $235B.
  • Repurchased 11.9M shares for $3.6B in 2025.
  • Quarterly dividend raised to $1.56 per share in 2026.
  • Maintains A Value Score and Zacks Rank #3 (Hold).
  • New model lowers out-of-pocket costs starting in 2027.
Risk Factors
  • 2024-2025 benefit expenses surged 27% and 12% due to higher medical costs.
  • Deteriorating margins as the 2025 medical cost ratio hit 84.4%.
  • Long-term debt of $30.9 billion far exceeds $7.7 billion cash reserves in 2025.
  • High leverage will continue to suppress interest expense relief going forward.
  • Shares dropped 3.4% YTD despite outperforming the sector's 13.5% decline.
Bullish Signals
  • CI shares have lost only 3.4% year-to-date, significantly outperforming the industry's average 13.5% decline.
  • The company trades at a forward P/E ratio of 8.61x, which is well below the industry average of 13.45x, indicating an attractive valuation.
  • Cigna has beat earnings estimates in each of the trailing four quarters with an average surprise of 2.7%.
  • Adjusted income from operations rose 4% year-over-year to 2025, driven by strong growth in the Evernorth Health Services segment.
  • Evernorth Health Services 2025 adjusted revenues increased 16% year-over-year to $235 billion.
  • The company successfully repurchased 11.9 million shares for approximately $3.6 billion in 2025 to support shareholder value.
  • The board increased the quarterly dividend to $1.56 per share in early 2026, up from $1.51 in 2025, signaling confidence in cash flow.
  • Cigna maintains a Value Score of A and holds a Zacks Rank #3 (Hold), suggesting solid prospects.
  • New transformative pharmacy benefits model will lower out-of-pocket costs by passing manufacturer discounts directly to customers starting in 2027.
Risk Factors
  • The company's total benefits and expenses escalated significantly, witnessing a year-over-year increase of 27% in 2024 and 12% in 2025 due to higher pharmacy, medical costs, and other benefit expenses.
  • The persistent escalation of expenses might weigh on the company's margin growth, with the medical cost ratio deteriorating 120 basis points year over year to 84.4% in 2025.
  • Cigna has been grappling with a significant debt level, holding long-term debt of $30.9 billion at the end of 2025, which is significantly higher than its cash balance of $7.7 billion.
  • The elevated leverage level is likely to keep pressure on the company's interest expenses going forward.
  • Cigna's shares have lost 3.4% year to date (YTD), even though they outperformed the industry's average 13.5% decline, suggesting relative weakness within a bearish sector.
Slightly Bullish +25

CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?

AI-generated analysis

This article compares CVS Health (CVS) and Cigna Group (CI) for retirement portfolios, highlighting divergent financial trajectories and investment profiles. The content notes that while CVS trades at approximately 11.3x trailing adjusted earnings with a 3.5% dividend yield generated on $76.07 in shares, it suffered a significant net income decline of 62.55% in FY2025 driven by a $5.7B goodwill impairment and $1.2B in litigation charges. In contrast, Cigna trades at roughly 9.4x trailing earnings with stronger earnings quality, reporting a 73.47% year-over-year net income increase to $5.957B, having beaten adjusted EPS estimates in all four quarters of 2025 by margins ranging from 0.65% to 6.17%. The analysis emphasizes Cigna's consistent execution and capital discipline, citing a pharmacy business (Evernorth) that grew revenue by 17% in Q4 2025 and expanded customers to 123.6 million, alongside an improvement in SG&A ratio from 5.9% to 5.0%. Over the past decade, Cigna has returned over 100% to shareholders, primarily through a $3.6B share repurchase program in 2025 and aggressive dividend growth, whereas CVS has seen long-term total returns of only 1.84% over ten years despite pharmacy segment momentum showing 9.7% same-store volume growth. CVS is positioned as a choice for retirees prioritizing current income and stability, offering a massive $402 billion revenue base and recent price performance gains of 17.32%, though it requires stabilization in its Health Care Benefits segment. Cigna is presented as the superior holding for long-term wealth compounding over a 10-to-15-year horizon due to its lower forward multiple of roughly 9.3x, shrinking share count, and proven consistency even after a recent price performance decline of 14.51%. The piece concludes that Cigna is likely the stronger holding for growth-oriented retirement investors despite CVS's attractive dividend yield.

📈 Cigna shows 73% net income growth with consistent quarterly earnings beats.

💰 CVS offers a 3.5% dividend yield but faces recent earnings declines.

🏛 Long-term investors favor Cigna, while retirees may prefer CVS's high yield.

📊 CVS Health trades at an 11.3x trailing adjusted earnings multiple compared to Cigna's 9.4x.

💰 CVS offers a 3.5% dividend yield with $2.66 in annualized dividends, while Cigna yields roughly 2.3%.

⚠️ CVS net income fell 62.55% year-over-year due to a $5.7B goodwill impairment and litigation charges.

📈 Cigna reported strong net income growth of 73.47% in FY2025, reaching $5.957 billion.

🏥 CVS Health Care Benefits segment faces a turnaround as operating income fell 45.28%.

💼 Cigna has beaten adjusted EPS estimates in all four quarters of 2025 with consistent execution.

📉 Cigna's Evernorth pharmacy business saw 17% revenue growth and expanded to 123.6 million customers.

💹 CVS generated $10.639 billion in operating cash flow for FY2025 compared to Cigna's guidance of at least $9.0 billion for the same period.

🔄 Over the past decade, Cigna has returned over 100% to shareholders versus just 1.84% for CVS.

📉 Cigna repurchased approximately $3.6 billion worth of shares in 2025 to shrink its share count.

🛒 CVS same-store prescription volume rose 9.7% while Pharmacy & Consumer Wellness revenue grew 12.4%.

🏃‍♂️ Cigna improved its SG&A ratio significantly from 5.9% to 5.0% year-over-year.

📉 While CVS stock is up 17.32% recently, Cigna stock has declined by 14.51% over the same period.

🎯 For long-term wealth building (10-15 years), Cigna is viewed as a stronger holding due to capital discipline.

⚖️ Retirees prioritizing current income may prefer CVS's higher yield and potential for turnaround upside.

Bullish Signals
  • Cigna net income grew 73.47% to $5.96B in FY2025.
  • Company beat EPS estimates for all four quarters of 2025.
  • Evernorth revenue rose 17% with 123.6M pharmacy customers.
  • SG&A ratio improved significantly from 5.9% to 5.0% YoY.
  • Cigna repurchased 11.9M shares for $3.6B in 2025.
  • Ten-year shareholder returns of 101.36% outpace the average.
  • Forward P/E is attractive at 9.3x based on strong earnings.
Risk Factors
  • Net income plummeted 62.55% driven by $5.7B impairment and charges.
  • Cash flow guidance reduced from $10B to at least $9B.
  • Operating income fell 45.28% despite pharmacy momentum gains.
  • Health Care Benefits segment must stabilize amid peer lag.
  • Stock underperformed peers long-term with 1.84% vs Cigna's 101%.
Bullish Signals
  • Cigna (CI) reported strong net income growth of 73.47% year-over-year, reaching $5.957 billion in FY2025.
  • The company demonstrates consistent execution by beating adjusted EPS estimates in all four quarters of 2025.
  • Cigna's Evernorth pharmacy business posted robust revenue growth of 17% in Q4 2025, with pharmacy customers expanding to 123.6 million.
  • Operating discipline is evident as the SG&A ratio improved significantly from 5.9% to 5.0% year-over-year.
  • Cigna has returned capital aggressively to shareholders by repurchasing approximately 11.9 million shares for $3.6 billion in 2025.
  • Over a long-term decade period, Cigna has compounded shareholder returns of 101.36%, far outpacing the historical average.
  • Cigna trades at an attractive valuation with forward P/E around 9.3x based on its strong earnings quality.
Risk Factors
  • CVS Health net income plummeted by 62.55% year-over-year in FY2025, a drop driven by a massive $5.7 billion goodwill impairment and approximately $1.2 billion in legacy litigation charges.
  • The company reduced its 2026 operating cash flow guidance from $10 billion to at least $9.0 billion, signaling potential financial pressure or margin deterioration ahead.
  • Operating income for CVS fell sharply by 45.28% year-over-year despite showing some pharmacy momentum.
  • While Cigna has strong growth, CVS faces a specific challenge that requires proving its Health Care Benefits segment can stabilize before becoming a stronger holding.
  • CVS stock is down significantly relative to peers in the long term over a decade, having returned just 1.84% compared to Cigna's 101.36%, which may indicate structural underperformance.
Bullish +75

The Cigna Group (CI) CEO Change Timing May Come As Surprise to Some Investors, According to Barclays

AI-generated analysis

The Cigna Group (NYSE: CI) recently announced a significant leadership transition on March 3, 2026, with outgoing CEO David Cordani stepping down and Brian Evanko, the current COO and former CFO, set to succeed him. Barclays, along with other analysts like Deutsche Bank, views this change as strategic continuity rather than a disruption, noting Evanko's extensive institutional experience and his status as one of the youngest CEOs in the healthcare services industry. While nearly 85% of analysts remain bullish as of March 9, 2026, Barclays points out that the timing of the CEO change coincides with the first year of a multi-year transformation of the company's pharmacy benefit management (PBM) model, which might catch some investors off guard given the ongoing business model shifts. Despite the stock falling more than 15% over the previous year to reach a price of approximately $269.66, insiders and analysts see significant upside potential, with figures suggesting roughly 23.67% room for growth compared to the healthcare plans sector which has declined by over 30%. The company reaffirmed its full-year 2026 earnings outlook on March 3, forecasting consolidated adjusted income from operations of at least $30.25 per share. Specific divisional targets include pre-tax adjusted income of at least $6.9 billion for Evernorth Health Services and at least $4.5 billion for Cigna Healthcare, reinforcing the firm's confidence in its strategic direction amidst industry pressures and AI-related market discussions highlighted in the broader commentary.

📈 CI trades at $269.66 with 23.67% upside despite a >15% annual decline.

👤 CEO Cordani steps down March 2026, succeeded by experienced CFO Evanko.

💹 Earnings outlook holds strong with ≥$30.25/share and sector outperformance.

- 📈 The Cigna Group (NYSE: CI) is currently trading at $269.66 with a projected 23.67% upside potential despite falling more than 15% over the previous year.

- 👤 CEO David Cordani is retiring as of March 3, 2026, to be succeeded by Brian Evanko, who previously served as CFO and COO.

- 🧔 Barclays notes that Evanko was always considered the natural successor due to his extensive institutional experience within the company.

- ⏰ The leadership transition timing may surprise investors because it coincides with the start of a multi-year transformation of the company's pharmacy benefit management (PBM) model.

- 💵 Cigna reaffirmed its 2026 earnings outlook, forecasting full-year consolidated adjusted income from operations of at least $30.25 per share.

- 🏥 The company expects pre-tax adjusted income for Evernorth to be at least $6.9 billion and for Cigna Healthcare to be at least $4.5 billion.

- 📊 Nearly 85% of analysts remained bullish on the stock as of March 9, 2026, viewing the changes as a reflection of strategic continuity amid industry pressures.

- 🏆 The Cigna Group has outperformed the broader healthcare plans sector, which declined by more than 30% over the same one-year period.

- 🤖 Analysts at Insider Monkey believe that while CI is a good investment, AI stocks may hold greater promise for delivering higher returns in shorter time frames.

- 📜 Cigna operates as a leading global health services provider focused on pharmacy benefits, healthcare solutions, and care management through its subsidiaries Evernorth Health Services and Cigna Healthcare.

Bullish Signals
  • Cigna (NYSE: CI) listed as top value stock by billionaires.
  • 85% of analysts remain bullish on Cigna as of March 2026.
  • CI trades at $269.66 with 23.67% upside despite prior decline.
  • Cigna outperformed healthcare plans sector which dropped over 30%.
  • CEO Brian Evanko offers institutional experience and fresh leadership.
  • Full-year income forecast reaches at least $30.25 per share.
  • Deutsche Bank rates Cigna Buy with strong analyst support.
Risk Factors
  • CEO change coincides with PBM transformation start.
  • Analysts shifting conviction from Cigna to AI stocks.
  • Article implies Cigna offers inferior risk-adjusted returns.
  • High AI upside suggests opportunity cost for Cigna.
Bullish Signals
  • Cigna Group (NYSE: CI) is included in the list of 11 best value stocks to invest in according to billionaires.
  • Nearly 85% of analysts remain bullish on the company as of March 9, 2026.
  • Despite a stock decline of more than 15% over the previous year, CI is currently trading at $269.66 with a 23.67% upside potential.
  • Cigna has outperformed the healthcare plans sector, which declined by more than 30% over the same period.
  • The company's CEO Brian Evanko brings extensive institutional experience and is highlighted as the natural successor to CEO David Cordani.
  • Evanko will be one of the youngest CEOs in the healthcare services industry, suggesting a fresh leadership perspective.
  • Cigna reaffirmed its long-term earnings outlook with a forecast for full-year consolidated adjusted income from operations of at least $30.25 per share.
  • The company expects pre-tax adjusted income for Evernorth of at least $6.9 billion and Cigna Healthcare of at least $4.5 billion.
  • Deutsche Bank has issued a Buy recommendation on Cigna (CI).
  • Piper Sandler continues to back the company's PBS strategy, issuing a minor PT cut while maintaining support.
Risk Factors
  • The timing of the CEO change is a concern as Cigna Group begins the first year of a multi-year transformation of its pharmacy benefit management (PBM) model, which Barclays notes may come as a surprise to some investors.
  • Despite the stock being included in 'best value' lists, analyst conviction shifts towards AI stocks, with the article suggesting AI stocks may hold greater promise for delivering higher returns within a shorter time frame compared to Cigna.
  • The article promotes alternative investments by directing readers to reports on an unnamed AI stock with purported "10,000% upside potential" and other high-growth strategies, implicitly suggesting Cigna offers inferior risk-adjusted returns.
  • Cigna faces a competitive landscape where the firm explicitly acknowledges that AI stocks are viewed as more promising alternatives for investors seeking performance, highlighting a potential opportunity cost.